HemaCare Corporation

Equities

HEMA

US4234981045

Healthcare Facilities & Services

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.08%	+0.24%

2020	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
2020	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI

Hemacare Corporation Reports Earnings Results for the Half Year Ended June 30, 2019

August 20, 2019 at 05:40 pm IST

HemaCare Corporation announced earnings results for the half year ended June 30, 2019. For the half year, the company announced sales was USD 19.454 million compared to USD 13.070 million a year ago. Net income was USD 4.474 million compared to USD 2.130 million a year ago.

Latest news about HemaCare Corporation

HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	02/20/02	CI
MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	22/20/22	CI
Charles River Laboratories International, Inc. completed the acquisition of HemaCare Corporation.	03/20/03	CI
Charles River Laboratories International, Inc. entered into a definitive agreement to acquire HemaCare Corporation for approximately $380 million.	16/19/16	CI
HemaCare Expands Its Product Portfolio with GMPrime™ Bone Marrow Aspirate	19/19/19	CI
HemaCare Corporation and Vital River Partner to Provide Human-Derived Biological Material to China	27/19/27	CI
Hemacare Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	20/19/20	CI
HemaCare Corporation Reports Earnings Results for the Year Ended December 31, 2018	26/19/26	CI
HemaCare Corporation announced that it has received $4.999999 million in funding from OBF Investments LLP	20/18/20	CI
HemaCare Corporation Moves its Global Headquarters to Northridge, California	06/18/06	CI
HemaCare Corporation Provides Starting Material for Three FDA Approved Cellular Therapies	14/18/14	CI
HemaCare Corporation Reports Unaudited Earnings Results for the Six Months Ended June 30, 2018	21/18/21	CI
HemaCare Corporation Announces Executive Appointments	17/18/17	CI
HemaCare Corporation Reports Earnings Results for the Full Year Ended December 31, 2017	08/18/08	CI
HemaCare Corporation and Charles River Laboratories International Inc. Announces Strategic Partnership to Accelerate Drug Discovery and Development	06/18/06	CI
HemaCare Corporation Reports Unaudited Earnings Results for the First Six Months Ended June 30, 2017	21/17/21	CI
HemaCare Signs Long Term Lease for Facility Relocation and Expansion	24/17/24	CI
HemaCare Corporation Reports Financial Results for the Year Ended December 31, 2016	13/17/13	CI
HemaCare Corporation Signs Distribution Agreement with Almog Diagnostic	20/17/20	CI
HemaCare Corporation announced that it expects to receive $5 million in funding from OBF Investments LLP	06/17/06	CI
HemaCare Signs Distribution Agreement with Accuresearch Korea, Inc	31/16/31	CI
HemaCare Corp. Reports Unaudited Earnings Results for the First Six Months Ended June 30, 2016	06/16/06	CI
HemaCare Corporation Signs Strategic Distribution Agreement with MT-Biological Science and Technology Co. Ltd	13/16/13	CI
HemaCare Corp. Expands its Offering of Stem Cell-Enriched Peripheral Blood	28/16/28	CI
HemaCare to Increase Bone Marrow Capability	21/16/21	CI

Chart HemaCare Corporation

Duration

Period

More charts

Company Profile

Charles River Laboratories Cell Solutions, Inc. is a cell sourcing provider for developers of cell therapies and basic research. The Company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. It offers a comprehensive and integrated portfolio of drug development products and services available from a single global provider, spanning the continuum from early research to the support of marketed products. Its products and services include Research Models & Services, Discovery Services Safety Assessment, Laboratory Sciences, Cell and Gene Therapy CDMO Solutions, Biologics Testing Solutions, Avian Vaccine Services, QC Microbial Solutions, Scientific & Regulatory Advisory Services, and Scientific Staffing, Training & Operations Support.

Sector

Healthcare Facilities & Services

More about the company

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
HEMACARE CORPORATION	+0.24%	35Cr
HCA HEALTHCARE, INC.	+18.44%	8.31TCr
CVS HEALTH CORPORATION	-28.96%	7.09TCr
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+3.59%	2.83TCr
LABORATORY CORPORATION OF AMERICA HOLDINGS	-7.16%	1.77TCr
FRESENIUS SE & CO. KGAA	+2.10%	1.74TCr
QUEST DIAGNOSTICS INCORPORATED	+1.45%	1.56TCr
REDE D'OR SÃO LUIZ S.A.	+8.62%	1.35TCr
FRESENIUS MEDICAL CARE AG	+7.90%	1.28TCr
NATERA, INC.	+71.36%	1.27TCr

Other Healthcare Facilities & Services